Yüklüyor......

Immune dysregulation as a driver of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Invest
Asıl Yazarlar: Shenderov, Kevin, Collins, Samuel L., Powell, Jonathan D., Horton, Maureen R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2021
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810481/
https://ncbi.nlm.nih.gov/pubmed/33463535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI143226
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!